– USA, CA – Claritas Pharmaceuticals, Inc. (TSX: KLY | OTC: KALTF) today announced the addition of Dr. Perenlei Enkhbaatar, MD, Ph.D., FAHA to its Board as an independent director, effective immediately.
Dr. Perenlei Enkhbaatar is an internationally renowned authority and leader on the biology and pathophysiology of nitric oxide and acute lung injury, and his appointment to the Board of Directors will further strengthen the Company’s position as a leader in the field of nitric oxide therapeutics.
“The addition of Dr. Enkhbaatar to the Company’s Board enhances and strengthens our focus on nitric oxide pharmaceuticals,” said CEO, Robert Farrell. “We previously announced the addition of Dr. Salvatore Cuzzocrea to our Board. Both Dr. Enkhbaatar and Dr. Cuzzocrea are internationally renowned authorities and leaders on the biology and pathophysiology of nitric oxide. Drs. Enkhbaatar and Cuzzocrea will help guide the Company’s development of R-107, our proprietary nitric oxide-releasing compound that is being developed as a treatment for coronavirus, COVID-19, and other viral infections. Dr. Enkhbaatar will be a strong strategic resource for Claritas, and we look forward to the contributions he will make.”
About Dr. Perenlei Enkhbaatar
Dr. Enkhbaatar currently serves as the Charles Robert Allen Professor and the Director of the Translational Intensive Care Unit in the Department of Anesthesiology at the University of Texas Galveston Medical Branch.
Following his medical training at the University of Saint Petersburg in Russia, Dr. Enkhbaatar served as a Senior Lieutenant physician in the Mongolian Army. He went on to receive his Ph.D. at Kumamoto University Graduate School of Medical Sciences in Japan. He then undertook his post-doctoral training in the Department of Anesthesiology, University of Texas Medical Branch in Galveston, Texas, under the mentorship of the late Professor Daniel Traber, the foremost authority over the last fifty years on the pathophysiology of acute lung injury. Upon Dr. Traber’s death, Dr. Enkhbaatar assumed the leadership of the research unit in Galveston and has further expanded its research prominence in the development of effective therapeutic approaches with special emphasis on tissue regeneration and stem cell biology.
For the past 25 years, Dr. Enkhbaatar has played a leading role in the elucidation of basic mechanisms of disease in acute lung injury and acute respiratory distress syndrome secondary to pneumonia, sepsis, toxic gas inhalation, and thermal injury associated with smoke inhalation. He has been at the forefront of pioneering therapeutic approaches to counter reactive oxidative and nitrosative stress. In recognition of these advances in the medical science of acute lung injury, Dr. Enkhbaatar has been awarded numerous federal grants, including funding from the National Institutes of Health, the American Heart Association, the Department of Defense, Shriners of North America, and the Office of Naval Research. His research advances have been presented at international conferences and in the publication of more than three hundred abstracts, one hundred and fifty-four original manuscripts in leading peer-reviewed journals, and twelve book chapters.
In recognition of his contributions to the field of cytokine storm induced acute lung injury, Dr. Enkhbaatar has been selected to serve on the Editorial Boards of leading journals in the fields of trauma and acute lung injury, including Critical Care Medicine, Shock, and Burn & Trauma, and has been invited to join numerous professional societies, including the Society of Critical Care Medicine, the American Burn Association, the Shock Society, the American Thoracic Society, the American Physiological Society, the American Heart Association, the Surgical Infection Society, and the Royal Society of Medicine.
Dr. Enkhbaatar brings expert knowledge of R-107 to Claritas, having carried out clinically relevant large animal studies showing its treatment benefit in experimental models of bacterial pneumonia, smoke inhalation and burn injury, and chlorine inhalational lung injury. As a world authority on the biological mechanisms of pulmonary damage in cytokine-storm-induced acute lung injury, Dr. Enkhbaatar is ideally positioned to appreciate the underlying pathophysiology of COVID-19 disease and to guide potential therapeutic approaches based on the provision of nitric oxide via the clinical administration of R-107.
About Claritas Pharmaceuticals
Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people’s lives.
For more information: https://claritaspharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.